Data / Form D filings / Surrozen, Inc./DE
Surrozen, Inc./DE: Form D filings
Surrozen, Inc./DE, a biotechnology company in South San Francisco, CA, filed 2 Form D notices with the SEC between 2024 and 2025. The latest, on April 8, 2025, reports $76.4 million sold of a $175 million offering to 29 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 171 OYSTER POINT BLVD, SUITE 400, South San Francisco, CA, 94080
- Phone
- (650) 489-9000
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1824893
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 8, 2025 | New notice | $174,999,955 | $76,402,277 | $98,597,678 | 29 | Mar 26, 2025 | sec.gov |
| Apr 19, 2024 | New notice | $193,015,962 | $193,015,962 | 18 | Apr 4, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Yang J. Li, Ph.D. | Executive Officer | |
| Anna J. Berkenblit, M.D. | Director | |
| Mary J. Haak-Frendscho, Ph.D. | Director | |
| David J. Woodhouse, Ph.D. | Director | |
| Craig Parker | Executive Officer, Director | |
| Charles Williams | Executive Officer | |
| Mace J. Rothenberg, M.D. | Director | |
| Shao-Lee J. Lin, M.D., Ph.D. | Director | |
| Tim J. Kutzkey, Ph.D. | Director | |
| Christopher J. Chai | Director | |
| Eric J. Bjerkholt | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Apr 7, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Surrozen, Inc./DE reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.